Page 18 - PD-L1 EbookV2 Flip PDF
P. 18
The Base Case (Scenario 1) looked at revenues predicted within the model from 2015 to
2019 in second line NSCLC. The projected cumulative base case value for a therapy label
dependent upon testing is $1.3 billion in the US market (Figure 1).
Figure 1. Drug revenue ($m) 2015-2019
Looking at the relative dollar impact of each optimized driver (cumulative five year revenues)
revealed that whilst optimized dosing in high expressing PD-L1 patients (>50%) is the
biggest single contributor, improving test accuracy and driving greater demand for testing
confer significant revenue gains (Figure 2).
Page 18 of 31
